UBS Group
ABUS icon

UBS Group’s Arbutus Biopharma ABUS Stock Holding History

UBS Group’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-100
Closed -$2K – 8444
2015
Q1 		$2K Buy
+100
New +$2.05K ﹤0.01% 8420

Other funds holding ABUS

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
WCM
Whitefort Capital Management New York $339M AUM 52.48% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

UBS Group's ABUS Position: Q1 2026 in Review

UBS Group increased its Arbutus Biopharma (ABUS) stake by 147% in Q1 2026, buying an estimated $950K and bringing the position to 364,471 shares worth $1.64M. The position accounts for ﹤0.01% of the portfolio, ranked #5147.

UBS Group first reported a position in ABUS in Q4 2014 and has held it in 42 quarters since. The position peaked at $3.52M in Q3 2025. 167 funds tracked by Wall St. Rank hold ABUS as of Q1 2026.

  • UBS Group held 364,471 shares of Arbutus Biopharma worth $1.64M as of Q1 2026.
  • UBS Group bought 217,179 Arbutus Biopharma shares in Q1 2026, an estimated $950K.
  • Arbutus Biopharma made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #5147 holding.
  • UBS Group first reported a position in Arbutus Biopharma in Q4 2014 and has held it in 42 quarters since.
  • UBS Group's Arbutus Biopharma position peaked at $3.52M in Q3 2025.
  • 167 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.